Orforglipron
First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.
Key Facts
- ClassificationCapsule — First oral non-peptide GLP-1 agonist in late-stage trials.
- Primary BenefitsFat Loss (9/10) · Gut Health (3/10)
- AdministrationOral
- Typical Dose12-36-120 mg oral daily in the morning. Titrate up gradually.
- Evidence StrengthEmerging · Community sentiment 8/10
Quick Facts
- From price
- Not stocked
- Type
- capsule
- Administration
- Oral
- Evidence
- emerging
- Studies referenced
- 0
- Community sentiment
- 8/10
- Stacks with
- 0 peptides
Top benefits
Dosing
12-36-120 mg oral daily in the morning. Titrate up gradually.
Benefit Profile
Not yet in our tracked vendor supply.
Orforglipron is still moving from clinical pipeline to research-chemical supply in the channels we monitor. We'll add pricing + vendor rows here as soon as a reference vendor carries it in stock. In the meantime, the mechanism and research summary on this page reflect published data only — not a purchase recommendation.
Questions about access routes? See our sourcing reference.
Related 🔥 Fat Loss Peptides
Other peptides strong in fat loss
GLP-1 drug (Ozempic/Wegovy) that suppresses appetite and burns fat.
Tirzepatide10/10Dual GLP-1/GIP drug (Mounjaro/Zepbound). Strongest weight loss peptide available.
Retatrutide10/10Triple-action weight loss drug hitting GLP-1, GIP, and glucagon receptors.
CagriSema10/10Next-gen dual semaglutide + amylin analog with strongest weight loss data.
Survodutide9/10Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim.
Mazdutide9/10Dual GLP-1/glucagon receptor drug with strong weight loss results.